CD274 and neoplasm: Recently, increasing evidence has shown that PD-L1 expression levels in tumor cells might affect the clinical response to anti-PD-1/PD-L1 therapies, and PD-L1 (+) patients have a better response rate to ICIs and better overall survival 39-44.